secwatch / observer
8-K/A filed May 21, 2026, 5:17 PM ET CIK 0000095572
other material confidence medium sentiment negative materiality 0.60

KiNRG provides audited financials for Trinity acquisition; FY2025 net loss $2.7M, going concern

KiNRG, Inc.

item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001213900-26-060156
form_type
8-K/A
ticker
null
cik
0000095572
company_name
KiNRG, Inc.
filed_at
2026-05-21T21:17:40+00:00
discovered_at
2026-05-21T21:20:00.191691+00:00
generated_at
2026-05-21T21:47:33.892767+00:00
sec_items
["9.01"]
event_type
other_material
sentiment
negative
materiality_score
0.6
calibrated_materiality_score
0.6
confidence
medium
secwatch_canonical_url
https://secwatch.observer/filing/0001213900-26-060156
json_url
https://secwatch.observer/filing/0001213900-26-060156.json
markdown_url
https://secwatch.observer/filing/0001213900-26-060156.md
text_url
https://secwatch.observer/filing/0001213900-26-060156.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/95572/000121390026060156/0001213900-26-060156-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/95572/000121390026060156/ea0291773-8ka1_kinrg.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Comparable filings

DCOM

Dime Commercial Bancshares name change effective; three executives amend employment agreements

Dime Community Bancshares, Inc. /NY/ June 1, 2026, 4:02 PM ET other_material Items 5.02, 5.03, 5.07, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

SYRE

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

ORKA

Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030

Oruka Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

PUBC

Purebase to receive 20% of net proceeds from CoreTer mining deal; waives corporate opportunities

Purebase Corp June 1, 2026, 3:42 PM ET other_material Items 1.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

VIASP

Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends

Via Renewables, Inc. June 1, 2026, 3:06 PM ET other_material Items 8.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

BUKS

CEO Christopher Reedy discloses ongoing cancer treatment; remains in role

BUTLER NATIONAL CORP June 1, 2026, 12:41 PM ET other_material Items 8.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

BGS

B&G Foods provides College Inn/Kitchen Basics acquisition financials: FY2025 revenue $124.9M, op loss $0.8M

B&G Foods, Inc. June 1, 2026, 11:52 AM ET other_material Items 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

CPSH

CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share

CPS TECHNOLOGIES CORP/DE/ June 1, 2026, 9:35 AM ET other_material Items 1.01, 5.03, 8.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR
accession 0001213900-26-060156
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.